Physician profile
Michael Rowley
NPI 1255593950
$3,798.97
in general payments reported to CMS, 2019-2025
21 companies · $605 in 2025
The $605 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,095 · 2022: $1,114 · 2023: $568 · 2024: $417 · 2025: $605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,589.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,462.82 | 2021-2025 | General - Biliary Devices, Therasphere Y90 Glass Microspheres 10 Gbq, Axios |
| Abbvie INC. | $586.66 | 2022-2025 | Skyrizi |
| E.R. Squibb & Sons, L.L.C. | $567.01 | 2021-2022 | |
| Madrigal Pharmaceuticals | $149.39 | 2025 | Rezdiffra |
| Janssen Biotech, INC. | $139.66 | 2023-2025 | Stelara, Tremfya, Simponi |
| Intercept Pharmaceuticals, INC. | $139.31 | 2023-2024 | Ocaliva |
| Celgene Corporation | $103.43 | 2022 | |
| Erbe USA INC | $102.96 | 2024-2025 | Vio3 |
| Takeda Pharmaceuticals U.S.A., INC. | $94.07 | 2022 | |
| Ardelyx, INC. | $92.08 | 2022 | |
| Ferring Pharmaceuticals INC. | $83.33 | 2022 | |
| Janssen Scientific Affairs, LLC | $49.37 | 2022 | |
| Conmed Corporation | $42.94 | 2022-2024 | Conmed Hemostasis, Conmed Biliary |
| Pfizer INC. | $37.44 | 2022-2023 | |
| Aimmune Therapeutics, INC. | $33.34 | 2025 | Zenpep |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Institutional INC. | $25.39 | 2023 | Hulio |
| Regeneron Healthcare Solutions, INC. | $20.95 | 2025 | Dupixent |
| Cook Medical LLC | $18.98 | 2021 | |
| Gilead Sciences, INC. | $18.46 | 2023 | |
| Nestle Healthcare Nutrition INC. | $16.52 | 2023 | |
| Celltrion USA INC. | $14.86 | 2025 | Vegzelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rowley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.